PC
CEROW

Periscope Capital’s CERo Therapeutics Warrants CEROW Stock Holding History

Periscope Capital’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-274,000
Closed -$3.97K – 253
2025
Q1 		$3.97K Hold
274,000
– – ﹤0.01% 190
2024
Q4 		$2.27K Sell
274,000
-151,534
-36% -$1.65K ﹤0.01% 191
2024
Q3 		$2.17K Sell
425,534
-2,100
-0.5% -$35 ﹤0.01% 243
2024
Q2 		$8.6K Sell
427,634
-163,866
-28% -$9.6K ﹤0.01% 251
2024
Q1 		$40.3K Sell
591,500
-365,598
-38% -$22.2K 0.01% 238
2023
Q4 		$25.6K Hold
957,098
– – ﹤0.01% 311
2023
Q3 		$68.5K Hold
957,098
– – 0.01% 338
2023
Q2 		$61.9K Hold
957,098
– – ﹤0.01% 402
2023
Q1 		$38.3K Hold
957,098
– – ﹤0.01% 571
2022
Q4 		$40.6K Buy
957,098
+26,300
+3% +$1.38K ﹤0.01% 598
2022
Q3 		$86K Buy
930,798
+630,998
+210% +$53.1K ﹤0.01% 641
2022
Q2 		$32K Hold
299,800
– – ﹤0.01% 796
2022
Q1 		$65K Buy
+299,800
New +$111K ﹤0.01% 873

Other funds holding CEROW

CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Periscope Capital's CEROW Position: Q2 2025 in Review

Periscope Capital sold out of CERo Therapeutics Warrants (CEROW) in Q2 2025, closing a stake of 274,000 shares — an estimated $3.97K sold.

Periscope Capital first reported a position in CEROW in Q1 2022 and held it in 13 quarters. The position peaked at $86K in Q3 2022. 23 funds tracked by Wall St. Rank hold CEROW as of Q2 2025.

  • Periscope Capital reported no remaining CERo Therapeutics Warrants position as of Q2 2025 after selling out during the quarter.
  • Periscope Capital sold 274,000 CERo Therapeutics Warrants shares in Q2 2025, an estimated $3.97K.
  • Periscope Capital first reported a position in CERo Therapeutics Warrants in Q1 2022 and held it in 13 quarters.
  • Periscope Capital's CERo Therapeutics Warrants position peaked at $86K in Q3 2022.
  • 23 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q2 2025.

Based on Periscope Capital's 13F filing for Q2 2025, filed 14 Aug 2025.